Trial Profile
A Study of BCMA CAR-T Cells for Patients With Relapse and Refractory Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs PRG 1801 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions
- 02 Nov 2017 New trial record